Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943173 · ClinicalTrials.gov registry record · Early Phase 1
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
A Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and Primary Peritoneal High Grade Serous Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03943173 is a Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and Primary Peritoneal High Grade Serous Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 127-participant average among 9 other Stage III Ovarian Cancer AJCC v8 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03943173, a Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and Primary Peritoneal High Grade Serous Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Chemotherapy
- PROCEDURE Therapeutic Conventional Surgery
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2027-06-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943173
The ClinicalTrials.gov registry entry for NCT03943173 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 9 other Stage III Ovarian Cancer AJCC v8 trials with a reported enrollment target (88% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stage III Ovarian Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.
NCT03943173 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03943173 about?
NCT03943173 is a clinical study titled "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery". This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03943173?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2019-06-07. Estimated completion is 2027-06-27.
What conditions does trial NCT03943173 study?
This clinical trial studies the following conditions: Stage III Ovarian Cancer AJCC v8, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation.
What interventions are being tested in trial NCT03943173?
The interventions under investigation include: Olaparib (DRUG), Chemotherapy (DRUG), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03943173?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943173 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Ovarian Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
RECRUITING · Early Phase 1
-
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
RECRUITING · Early Phase 1
-
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
RECRUITING
-
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
RECRUITING · NA
-
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
RECRUITING · Phase 2
-
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Stage III Ovarian Cancer AJCC v8
All registered trials for this condition
Primary Peritoneal High Grade Serous Adenocarcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.